Wedbush Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $55
Benzinga Newsdesk 9 months ago
NewsPrice TargetAnalyst Ratings
Wedbush analyst Laura Chico maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and raises the price target from $46 to $55.
Wedbush analyst Laura Chico maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and raises the price target from $46 to $55.